Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/47036
Title: | The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting |
Authors: | Rishko, Oleksandr A. Derbak, Mariya A. Ihnatko, Yaroslav Y. Dankanych, Yevheniia Е. Bletskan, Myroslava M. Krasnova, Anatolija A. Mashura, Hanna Y. Рішко, Олександр Адальбертович Дербак, Марія Антонівна Данканич, Євгенія Еміліянівна Блецкан, Мирослава Михайлівна Краснова, Анатолія Анатоліївна Машура, Ганна Юріївна |
Keywords: | arterial hypertension, type 2 diabetes mellitus, body weight, dapagliflozin |
Issue Date: | 2022 |
Publisher: | Aluna publishing hause |
Citation: | Rishko O. The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting/ O. Rishko, M. Derbak, Y. Ihnatko a. o. // Wiadomości Lekarskie : monthly journal VOLUME LXXV. – ISSUE 10. – 2022. – P. 2397-2401. |
Abstract: | The normalization of blood pressure, elimination of heart failure symptoms on the background of increased ejection fraction, improved indicators of the functional capacity of the kidneys, and a decrease in the degree of proteinuria/albuminuria were noted after treatment. The patients had an easier time losing weight (body mass index and waist circumference decreased; p<0.05) and decreased levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). None of the monitored patients had cases of hypoglycemia or urinary tract infection. The number and/or doses of antihypertensive, hypouricemic and diuretic drugs were gradually reduced. Conclusions: Using dapagliflozin in a standard dose of 10 mg/day in the complex therapy of patients with T2DM in combination with arterial hypertension and overweight contributes not only to the normalization of blood pressure, but also to a reduction in body weight and waist circumference. The proposed therapy can be an alternative for the treatment of patients with T2DM with concomitant overweight or obesity, arterial hypertension, with or without heart and/or renal failure as a first-line antidiabetic drug. |
Type: | Text |
Publication type: | Стаття |
URI: | https://dspace.uzhnu.edu.ua/jspui/handle/lib/47036 |
Appears in Collections: | Наукові публікації кафедри факультетської терапії |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
THE CLINICAL EXPERIENCE OF THE EFFECTIVE USE OF.pdf | 143.58 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.